Alexandra Rojek
@AlexandraRojek
Followers
400
Following
2K
Media
45
Statuses
329
Heme/Onc Instructor @UCCancerCenter and @KlineLabUChi - lymphomas and cellular therapy. Views are my own.
Chicago, IL
Joined May 2014
Very honored to receive this award alongside such incredible colleagues @AAnandappa and @Charlie_S_Dai, and excited for the promise of better understanding responses to cell therapy made possible by it! @KlineLabUChi @UChicagoHemOnc.
Three clinicians with exceptional promise and novel approaches to fighting cancer have been named the 2025 recipients of the Damon Runyon Physician-Scientist Training Award.
3
3
27
RT @UChicagoHemOnc: ASCO ended over a week ago, but we're still thinking about how great it was! Highlights included:.-@SoniSmithMD's first….
0
4
0
RT @majorajay: From @KlineLabUChi in @BloodJournal: multi-omic characterization of 4 'immune quadrants' in DLBCL, with better response to b….
0
16
0
RT @UChicagoHemOnc: Congratulations to our Section Chief, Dr. @SoniSmithMD new electee to the @ASCO Board of Directors as the Designated Me….
0
5
0
along with an excellent editorial featuring this report and other work published examining outcomes from an EBMT study and the overlap and differences therein
ascopubs.org
0
0
1
This original article confirms findings from randomized studies on GVHD-prophylaxis strategies to improve long-term pt outcomes, particularly for patients with HLA-mismatched donors available, which are more common among minority ancestry patients
ascopubs.org
PURPOSEAccess to allogeneic hematopoietic cell transplantation (HCT) remains limited among persons of non-European ancestry if human leukocyte antigen (HLA) matching is required. We evaluated whether...
1
0
1
RT @DrJFriedberg: Amazing collaborations in this successful @theNCI study led by Dr. Herrera. @SWOG @eaonc @COGorg @CDNCancerTrials @ALLIA….
nejm.org
Incorporating brentuximab vedotin into the treatment of advanced-stage classic Hodgkin’s lymphoma improves outcomes in adult and pediatric patients. However, brentuximab vedotin increases the toxic...
0
34
0
RT @KlineLabUChi: We’re excited to see outstanding science talks at the Jonas Center for Cellular Therapy Symposium today @UChicagoHemOnc a….
0
4
0
RT @Anand_88_Patel: The final version of our @e_JHaem paper on intensive chemo strategies in CBF-AML is available! @AlexandraRojek #leusm….
onlinelibrary.wiley.com
Core-binding factor acute myeloid leukemia (CBF-AML) is characterized by the presence of inv(16)/t(16;16) or t(8;21) and is classified as a favorable risk by the 2022 European LeukemiaNet (ELN)...
0
8
0
RT @Anand_88_Patel: Our analysis of intensive chemo (IC) in CBF-AML (200 pt) is out in @e_JHaem! Kudos to lead author @AlexandraRojek . We….
0
22
0
An amazing start to #AACRMBCO24 with @UCHemOncFellows colleagues focusing on translational science in oncology! With some gorgeous summer days and scenery as a bonus 😎 @AACR @UChicagoHemOnc @cannova_joe @theproffermd
0
2
16
RT @barrybutler9: Triple Strike at 1221am on Monday morning. Simultaneous lightning strikes on the Hancock, Trump Chicago and Sears Tower….
0
3K
0
RT @JCO_ASCO: #JCO welcomes our onboarding editorial fellows, Ayse Ece Cali Daylan, @MSHughes_MD, Peter Li, Joseph Mathew & @lcshihmd! http….
0
5
0
So excited to see this dream team take on the @JCO_ASCO fellowship!! And excited to be a part of the journey as well. Congrats!! 🥳.
An honor and privilege to serve as a 2024-2025 @JCO_ASCO Editorial Fellow under the one and only @SLentzsch as my primary mentor--not just in the lab and the clinic--alongside my good friend @AlexandraRojek!.
0
0
4
It’s been an honor and such a phenomenal learning experience to be a @JCO_ASCO editorial fellow this past year along with @GCarvalho_MD @RohitBanwar and Subodh Selukar - grateful to have learned from @SLentzsch and @DrJFriedberg among so many others!! @ASCO #ASCO24
1
3
27
RT @UCHemOncFellows: ASCO weekend this year means celebrating @UCCancerCenter’s 50th anniversary in style with some Chicago architecture! W….
0
7
0
Other insightful analysis and comments written by @NehaMehtaShahMD and Dr. Horwitz in an associated editorial on what we can learn from this negative study in PTCL where better therapies and better-designed studies are sorely needed! .
ascopubs.org
0
0
1
This updated analysis study finds significant benefit in the TFH lymphoma subgroup, with a prolonged PFS for this group with the addition of romidepsin to CHOP backbone - a known epigenetic-targeting therapy for this potentitally susceptible TFH subgroup.
ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or...
1
0
1
The Ro-CHOP study by the LYSA group also initially published in @ASCO_JCO did not find a benefit in PFS, response rates, or OS in the full study population, and increased sAEs.
ascopubs.org
PURPOSERomidepsin, a histone deacetylase inhibitor, has demonstrated activity in relapsed or refractory peripheral T-cell lymphoma (PTCL) as a single agent. Cyclophosphamide, doxorubicin, vincristi...
1
0
0